CytomX Therapeutics, Inc. (CTMX) Stock Analysis — Probabli.AI
AI-powered analysis for CTMX (CytomX Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $4.45 · Market cap: $826.0M · AI outlook: Bullish
CytomX Therapeutics, focusing on innovative oncology treatments, currently represents a high-risk, high-reward investment. Its strong analyst consensus, promising pipeline reports, and strategic partnerships present considerable upside potential, particularly in the mid-to-long-term horizons. However, the competitive and regulatory nature of its field introduces risks that should not be…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 40% · Bear 15%
- 1-year price estimates — P10: $4 / P50: $7 / P90: $12
- CytomX Therapeutics has strong analyst support, recent positive clinical results, and strategic partnerships. These indicate significant potential upside, albeit investors should remain cautious due to the competitive…
5-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 5-year price estimates — P10: $4 / P50: $17 / P90: $45
SWOT Highlights
- Strength: Innovative cancer therapeutics pipeline
- Strength: Strategic partnerships, including financial backing
- Risk: Negative revenue growth expectations
- Risk: Challenges in commercialization
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate CTMX a BUY with a mean price target of $11.9.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
CTMX forecast details · CTMX sentiment details · CTMX insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.